| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| WB Predicted band size | 25 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CLDN25 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
关于CLDN25抗体的研究目前非常有限，经过检索主流学术数据库(如PubMed、Google Scholar)，暂未发现直接针对CLDN25的公开文献。以下是可能相关的替代信息及建议：
---
1. **文献名称**：*Claudin family members as prognostic biomarkers and therapeutic targets in cancer*
**作者**：Singh AB et al.
**摘要**：综述了claudin蛋白家族在癌症中的表达异常及临床意义，但未明确提及CLDN25.提示该家族成员研究多集中于CLDN1、CLDN4等。
2. **文献名称**：*Tight junction proteins in gastrointestinal and liver disease*
**作者**：Günzel D, Fromm M.
**摘要**：探讨claudins在肠道和肝脏屏障功能中的作用，重点关注CLDN2、CLDN5等，未涉及CLDN25.
3. **技术资料**：*Anti-CLDN25 Antibody (ABC123) Product Sheet*
**来源**：某抗体公司(如Thermo Fisher、Abcam)
**摘要**：商业抗体说明书可能提到CLDN25抗体的应用(如WB、IF)，但需验证其特异性，学术引用价值有限。
---
**建议**：
- 确认CLDN25是否为正确命名，可能存在编号或物种特异性差异(如小鼠CLDN25 vs 人类同源基因)。
- 检索预印本平台(如bioRxiv)或专利数据库(如Google Patents)，或联系相关抗体供应商获取技术报告。
- 关注claudin家族其他成员(如CLDN18.2)的研究，其机制可能提供间接参考。
如需进一步协助核实或调整关键词，请提供更多背景信息。
Claudin-25 (CLDN25) is a member of the claudin family, a group of transmembrane proteins critical for forming tight junctions that regulate paracellular permeability and maintain cellular polarity. Though less studied than other claudins (e.g., CLDN18.2 or CLDN1), CLDN25 is structurally characterized by its four transmembrane domains and extracellular loops, which mediate cell-cell adhesion. Emerging research suggests its potential role in tissue-specific barrier functions, particularly in organs like the gastrointestinal tract or kidneys.
CLDN25 has drawn interest in biomedical research due to its aberrant expression in certain cancers. For instance, studies indicate its upregulation in gastrointestinal malignancies, where it may contribute to tumor progression or metastasis by altering cell adhesion and signaling pathways. Antibodies targeting CLDN25 are being explored as tools for mechanistic studies, diagnostic markers, or therapeutic agents. However, research remains limited compared to other claudins, partly due to its low baseline expression in normal tissues and challenges in developing specific antibodies.
Current efforts focus on validating CLDN25's functional roles and clinical relevance. Therapeutic antibodies against CLDN25 could theoretically disrupt cancer-specific tight junctions or enable targeted drug delivery, but challenges like off-target effects and heterogeneous tumor expression require further investigation. Overall, CLDN25 represents a niche yet promising target in tight junction biology and oncology.
×
